A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.

29
Mar
Date 29 marzo, 2017

A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.

Author maller
Ciudad Universitaria, Pabellón II 4º Piso CP: C1428EGA   |   Ciudad Autónoma de Buenos Aires, Argentina   |   Teléfonos: (+54-11) 4788-5755 o 528-58710 / Fax: 4788-5755